clinical trial · NCT07811882
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1)
Uncomplicated Plasmodium Falciparum MalariaKAE609 (Cipargamin)SoC (Coartem)INE963
brief summary
This is Cohort B1 of the Platform study (NCT05750628) to evaluate the efficacy and safety of INE963 + Cipargamin in participants with uncomplicated Plasmodium falciparum malaria.
started
Oct 10, 2025
primary completion
Jun 17, 2026
completion
Jul 1, 2026
last updated
Sep 10, 2026
detailed description
The Cohort B1 of this Platfom study (NCT05750628) is the open-label, randomized, two-arm combination therapy evaluating a dose of up to two anti-malarial agents as a loose combination vs. standard of care (SoC), Coartem in adult and adolescent participants.
official title
A Multi-part, Multi-center PLATform Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Anti-malarial Agents Administered as Monotherapy and/or Combination Therapy IN Participants With Uncomplicated Plasmodium Falciparum Malaria
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol